Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAIDA
说明： Potent and selective group I mGlu antagonist
别名： UPF 523
化学名： (RS)-1-Aminoindan-1,5-dicarboxylic acid
纯度： ≥98% (HPLC)
生物活性 for AIDA
AIDA is a relatively potent and selective antagonist of group I metabotropic glutamate receptors (mGlu1a), having no effect on group II (mGlu2) or group III (mGlu4) receptors expressed individually in baby hamster kidney cells. Has no effect on ionotropic glutamate receptors. Centrally active following systemic administration in vivo.
技术数据 for AIDA
| 分子量 | 221.21 |
| 公式 | C11H11NO4 |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 168560-79-0 |
| PubChem ID | 2071 |
| InChI Key | LSTPKMWNRWCNLS-UHFFFAOYSA-N |
| Smiles | NC2(C(O)=O)C1=CC=C(C(O)=O)C=C1CC2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for AIDA
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| 1.1eq. NaOH | 22.12 | 100 |
制备储备液 for AIDA
以下数据基于产品分子量 221.21。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.52 mL | 22.6 mL | 45.21 mL |
| 5 mM | 0.9 mL | 4.52 mL | 9.04 mL |
| 10 mM | 0.45 mL | 2.26 mL | 4.52 mL |
| 50 mM | 0.09 mL | 0.45 mL | 0.9 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for AIDA
参考文献 for AIDA
参考文献是支持产品生物活性的出版物。
Moroni et al (1997) Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J.Pharmacol.Exp.Ther. 281 721 PMID: 9152378
Nielsen et al (1997) Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats. Eur.J.Pharmacol. 326 105 PMID: 9196260
Pellicciari et al (1995) 1-Aminoindan-1,5-dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J.Med.Chem. 38 3717 PMID: 7562903
If you know of a relevant reference for AIDA, please let us know.
关键词: AIDA, AIDA supplier, Potent, selective, group, I, antagonist, Group, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, UPF523, UPF, 523, (Metabotropic), 0904, Tocris Bioscience
9 篇 AIDA 的引用文献
引用文献是使用了 Tocris 产品的出版物。 AIDA 的部分引用包括：
Ady et al (2014) Type 1 metabotropic glutamate receptors (mGlu1) trigger the gating of GluD2 δ glutamate receptors. J Neurosci 15 103 PMID: 24357660
Mahler et al (2014) Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Proc Natl Acad Sci U S A 19 49 PMID: 23017017
Cassé et al (2012) Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32 5186 PMID: 22496564
Wibrand et al (2010) Differential regulation of mature and precursor microRNA expression by NMDA and metabotropic glutamate receptor activation during LTP in the adult dentate gyrus in vivo. Eur J Neurosci 31 636 PMID: 20384810
Saitoh et al (2016) Glutamate signals through mGluR2 to control Schwann cell differentiation and proliferation Scientific Reports 6 29856 PMID: 27432639
De-May and Ali (2013) Cell type-specific regulation of inhibition via cannabinoid type 1 receptors in rat neocortex. J Neurophysiol 109 216 PMID: 23054605
Shin et al (2008) Dendritic glutamate release produces autocrine activation of mGluR1 in cerebellar Purkinje cells. EMBO Rep 105 746 PMID: 18174329
Yeckel et al (1999) Multiple forms of LTP in hippocampal CA3 neurons use a common postsynaptic mechanism. Nat Neurosci 2 625 PMID: 10404192
Pan et al (2004) Effects of the group I metabotropic glutamate receptor agonist, DHPG, and injection stress on striatal cell signaling in food-restricted and ad libitum fed rats. BMC Neurosci 5 50 PMID: 15579204
您是否知道使用了 Tocris AIDA 的优秀论文？ 请告知我们.
AIDA 的评论
目前没有该产品的评论。 Be the first to review AIDA and earn rewards!
Have you used AIDA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.